TeachableMedicalNews article 11302019
Teachable moment in classrooms:
- Cellular basis of life chapter – receptors on cell membranes bind ligands
- general senses chapter – unconventional types of pain
- general senses chapter – pharmaceuticals of pain control
- immune system chapter – antibodies as pharmaceuticals
The news item: A new injectable treatment for cluster headaches has recently been in the news:
Emgality Receives First FDA Approval for Treating Cluster Headache
US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
The article mentions the similarity of the pain of cluster headaches to that of migraines, and the approval of the drug Emgality (galcanazumab).
So, Why Do I Care??
About 1 million people suffer from a debilitating disorder, cluster headaches, in the USA. While there are several therapeutic approaches to cluster headaches, but their effectiveness varies, and many of those treatments have unpleasant side effects.
Plain English, Please!!! First, let’s talk about cluster headache. Cluster headache a quick onset and intensely painful type of headache. That pain makes patients disfunctional, and many cases the pain wakes them up at night, and, so, that is why this disorder is so debilitating. The headaches happen during a particular time of the day, because these headaches are linked to the body’s own internal clock.
Second, let’s talk about pain, this warning signal of our nervous system. We sense pain when tissue damage triggers nerve impulses in the nerve cells of the damaged body area, and those neurons conduct the nerve impulse to the brain
Third, let’s talk about this new treatment for cluster headache. Because cluster headache is not the result of tissue damage, common pain killers don’t work well on cluster headache pain. Many years of research identified a chemical that trigger cluster headache pain; that chemical is called calcitonin gene related peptide (CGRP). Cluster headaches happen when CGRP reaches receptors on neurons in the brain. So, how can you block the action of that peptide? Imagine a football game where the defensive tackle wraps his arms around the running back to keep him out of the end zone. The drug mentioned in the article, galcanezumab, acts like a defensive tackle wrapping arms around the running back CGRP, and keeping it away from receptors on neurons in the brain. The defensive tackle, galcanezumab, can target CGRP only, because galcanezumab is a modified antibody, a protein made by immune system cells to specifically target invaders in the body. As antibodies are proteins, they can not be taken orally, but have to be injected.